PACIFIC BIOSCIENCES OF CALIFORNIA overview

PacBio to Report Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023 PR Newswire MENLO PARK, Calif., Feb. 2, 2023 MENLO PARK, Calif. , Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at:...

Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock PR Newswire MENLO PARK, Calif., Jan. 24, 2023 MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has granted the underwriters a 30-day option to...

Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock PR Newswire MENLO PARK, Calif., Jan. 24, 2023 MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of...

PacBio Celebrates Nature Methods Naming Long-Read Sequencing "Method of the Year" PR Newswire MENLO PARK, Calif., Jan. 13, 2023 MENLO PARK, Calif. , Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022." Nature Methods had recognized the impact of long-read sequencing in a variety of groundbreaking studies, including those...

PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022 PR Newswire MENLO PARK, Calif., Jan. 9, 2023 PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems...

PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration PR Newswire MENLO PARK, Calif., Jan. 9, 2023 MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo , Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain...

PacBio to Present at 41st Annual J.P. Morgan Healthcare Conference PR Newswire MENLO PARK, Calif., Dec. 28, 2022 MENLO PARK, Calif. , Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference: Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023 , at approximately 5:15 PM PT ....

PacBio and Boston Children's Hospital Collaborate to Investigate Novel Variants Inaccessible by Short-Read Sequencing PR Newswire MENLO PARK, Calif., Dec. 6, 2022 Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif. , Dec. 6, 2022 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the C hildren's R are D isease C...